---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-323729"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2026-07-29T20:10:17+00:00"
generated_at: "2026-07-29T20:11:32.225916+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Glaukos Q2 net sales $185.6M (+50% YoY); raises FY2026 guidance to $680-700M

## Summary
- Record net sales $185.6M, up 50% YoY; U.S. glaucoma sales $118.5M (+64%).
- GAAP net loss $18.4M ($0.31/sh); non-GAAP net loss $8.3M ($0.14/sh), improved from $19.7M loss a year ago.
- Gross margin 82% (non-GAAP 85%), up from 78% (83%) YoY.
- Raised 2026 net sales guidance to $680-700M from prior $620-635M.
- Cash $289.3M, no debt; cites iDose TR and Epioxa as growth drivers.

## SEC filing metadata
- accession: 0001193125-26-323729
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2026-07-29T20:10:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000119312526323729/0001193125-26-323729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000119312526323729/gkos-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-323729
- JSON: https://secwatch.observer/filing/0001193125-26-323729.json
- Plain text: https://secwatch.observer/filing/0001193125-26-323729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.